The estimated Net Worth of Bros. Advisors Lp Baker Bro... is at least $113 million dollars as of 12 August 2016. Bros Bro owns over 4,046,590 units of Biocryst Pharmaceuticals stock worth over $72,804,155 and over the last 9 years Bros sold BCRX stock worth over $40,465,900.
Bros has made over 7 trades of the Biocryst Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently Bros sold 4,046,590 units of BCRX stock worth $20,232,950 on 12 August 2016.
The largest trade Bros's ever made was selling 4,046,590 units of Biocryst Pharmaceuticals stock on 12 August 2016 worth over $20,232,950. On average, Bros trades about 1,269,419 units every 30 days since 2016. As of 12 August 2016 Bros still owns at least 9,418,390 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Bros Bro stock trades at the bottom of the page.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... et Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: